Health care utilization and costs of a support program for patients living with the human immunodeficiency virus and tuberculosis in Peru
METHODS: We compared co-infected patients receiving Community-Based Accompaniment with Supervised Antiretrovirals (CASA) with matched patients receiving standard of care (control group) in two health districts of Lima, Peru. We recorded clinical outcomes, costs of the intervention, and health care utilization by each patient during 24 months of follow-up.
RESULTS: There were 33 patients in each group, representing 58.0 person-years (py) in the CASA group and 45.6 py in the control group. At 24 months of follow-up, the CASA group had a lower hazard of dying or defaulting from treatment (HR adj 0.34, 95%CI 0.12–0.98), experienced fewer hospital days (IRR adj 0.37, 95%CI 0.14–0.99) and had fewer out-patient visits (IRR adj 0.75, 95%CI 0.63–0.89). Assigning costs to significantly different measures of health care utilization using WHO-CHOICE (World Health Organization–Choosing interventions that are cost effective) data, CASA was associated with savings of US$551/py. Considering intervention costs of US$2097/py, the net costs of CASA were US$1546/py.
CONCLUSIONS: Our intervention was associated with clinical improvements and reduced health care utilization, which significantly offset the cost of the intervention over 2 years of follow-up.
Document Type: Regular Paper
Affiliations: 1: Massachusetts General Hospital and Harvard School of Public Health, Boston, Massachusetts, USA 2: Socios en Salud, Carabayllo, Lima, Peru 3: Peruvian HIV Program, Ministerio de Salud, Lima, Peru 4: Socios en Salud, Carabayllo, Lima, Peru; and Partners in Health, Boston, Massachusetts, USA 5: Hospital Nacional Hipolito Unanue, Lima, Peru 6: Hospital Dos de Mayo, Lima, Peru 7: Partners in Health, Boston, Massachusetts, USA 8: Partners in Health, Boston, Massachusetts, USA; and Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA
Publication date: 2011-03-01
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites